Wed.Sep 21, 2022

Cell therapy startup Carisma merges with troubled Sesen in bid for Wall Street

Bio Pharma Dive

The deal results from a strategic review Sesen, formerly known as Eleven Biotherapeutics, undertook after the FDA rejected its top drug last year

Drugs 163

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on

Fierce Pharma

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on. fkansteiner. Wed, 09/21/2022 - 10:20

Sales 87
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Novartis warns of sales hit after federal court turns back patent appeal

Bio Pharma Dive

The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya

Sales 146

NICE says yes to BeiGene’s Brukinsa after Scottish nay

Pharma Phorum

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL).

Drugs 83

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’

Bio Pharma Dive

The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences

Patient centricity is becoming business critical for pharma

Pharma Phorum

New book sets the pharmaceutical industry on a course for bridging the patient centricity optimism gap. Bridging the gulf between patient centricity ambition and reality has never been more important for pharma – luckily, this seemingly insurmountable goal isn’t as far out of reach as many envision.

More Trending

Fennec finally pushes drug to prevent chemotherapy-induced hearing loss across the FDA finish line

Fierce Pharma

Fennec finally pushes drug to prevent chemotherapy-induced hearing loss across the FDA finish line. esagonowsky. Wed, 09/21/2022 - 09:58

Drugs 82

No Walk in the Park: JAMA Editorial Calls for More Park Prosecutions; We Disagree

The FDA Law Blog

By Jeffrey N.

Avrobio receives FDA rare pediatric disease status for cystinosis therapy

Pharmaceutical Technology

Avrobio has received rare pediatric disease designation from the US Food and Drug Administration (FDA) for its investigational gene therapy, AVR-RD-04, designed to treat cystinosis.

Spectrum, Oncopeptides' oncology drugs have much to overcome heading into FDA adcomm

Fierce Pharma

Spectrum, Oncopeptides' oncology drugs have much to overcome heading into FDA adcomm. kdunleavy. Wed, 09/21/2022 - 06:56

Drugs 80

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

Cell-based therapies set to become major players in the osteoarthritis market

Pharmaceutical Technology

Osteoarthritis (OA) is a slowly progressive joint disease that is a major cause of disability and pain among the elderly, second only to cardiovascular disease.

Patch vaccine innovator Vaxxas receives $8.2m grant to scale-up manufacturing facility

BioPharma Reporter

Vaxxas will receive an AU$8.2m second round grant as part of the Australian Federal Governmentâs Modern Manufacturing Initiative (MMI) to support the manufacturing scale-up of its technology that enables vaccines to be applied to the skin using a small patch. Bio Developments

Industrial automation hiring levels in the pharmaceutical industry rose in August 2022

Pharmaceutical Technology

The proportion of pharmaceutical companies hiring for industrial automation related positions rose in August 2022 compared with the equivalent month last year, with 52% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 49.7%

56

AstraZeneca: Redefining Cancer Care

Pharmaceutical Commerce

AZ’s Greg Rossi talks about the company’s oncology activities and his vision for the future of cancer treatment.

52

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Future of work hiring levels in the pharmaceutical industry rose in August 2022

Pharmaceutical Technology

The proportion of pharmaceutical companies hiring for future of work related positions rose in August 2022 compared with the equivalent month last year, with 46.9% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 43.7%

52

Lannett, Par join the list of companies struggling to supply Adderall and its generics

Fierce Pharma

Lannett, Par join the list of companies struggling to supply Adderall and its generics. zbecker. Wed, 09/21/2022 - 08:46

60

Pfizer and CytoReason extend partnership for AI-driven drug discovery

Pharmaceutical Technology

Pfizer and CytoReason have expanded their multi-year collaboration to leverage the latter’s artificial intelligence (AI) technology to discover and develop the former’s drug programmes.

AstraZeneca’s Tezspire for severe asthma gets green light in EU

Pharma Phorum

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease.

Industrial automation hiring levels in the pharmaceutical industry rose in August 2022

Pharmaceutical Technology

The proportion of pharmaceutical companies hiring for industrial automation related positions rose in August 2022 compared with the equivalent month last year, with 52% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 49.7%

52

Film dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for film dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Film dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions. Infographic

Drugs 80

Rocket agrees to acquire biotech firm Renovacor

Pharmaceutical Technology

Rocket Pharmaceuticals has entered a definitive agreement for the acquisition of biotechnology firm Renovacor in an all-stock equity deal worth nearly $53m, or $2.60 for each share. Renovacor focuses on offering precision treatments for genetic cardiovascular and mechanistically-related ailments.

J&J Opens San Francisco R&D Campus

Pharmaceutical Commerce

Will feature drug discovery, gene and RNA therapy technology.

RNA 40

Takeda farms out cancer drug alisertib to Puma Biotech

Pharma Phorum

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won’t be taking the drug forward itself.

HR 56

Building up Australia’s vaccine manufacturing capacity

BioPharma Reporter

Almost all of Australiaâs vaccines are imported: creating a potential crisis in a pandemic. As a result, the country is setting out its strategy for developing vaccine manufacturing capabilities. Upstream Processing

New patent expiration for Chiesi drug BETHKIS

Drug Patent Watch

Annual Drug Patent Expirations for BETHKIS Bethkis is a drug marketed by Chiesi and is included in one NDA. It is available from two suppliers. There are three patents protecting…. The post New patent expiration for Chiesi drug BETHKIS appeared first on DrugPatentWatch - Make Better Decisions.

How a once-weekly insulin could disrupt diabetes management – the pharmaphorum podcast

Pharma Phorum

Insulin has been used to manage diabetes for a century, and while many advances have been made for people with both type 1 and type 2 diabetes – many more continue to be made.

GSK cancer drug Zejula to face renewed FDA scrutiny during November adcomm

Fierce Pharma

GSK cancer drug Zejula to face renewed FDA scrutiny during November adcomm. zbecker. Wed, 09/21/2022 - 15:21

Drugs 52

Is There a Coffee Shortage Brewing?

XTalks

Coffee inventories in South America are declining so severely that reserves are predicted to be extremely low, but can we expect a coffee shortage?

Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court

Fierce Pharma

Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court. zbecker. Wed, 09/21/2022 - 10:51

Sales 52

How Air Pollution Triggers Lung Cancer + Scientists Develop Parkinson’s Test Based on Woman’s Ability to Smell It – Xtalks Life Science Podcast Ep. 78

XTalks

In this episode, Ayesha shared new research about how scientists at the Francis Crick Institute and University College London have found a mechanism of action to explain how air pollution may cause lung cancer in non-smokers.

13th PM Society Digital Awards – celebrating creative innovation

Pharma Phorum

Germany’s ProBioGen supporting City of Hope’s CMV vaccine program

BioPharma Reporter

The two entities have signed a non-exclusive licensing agreement. Markets & Regulations

Novartis knocked back again in bid to block Gilenya generics in US

Pharma Phorum

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. The US Court of Appeals for the Federal Circuit (CAFC) has denied the Swiss pharma group’s petition to rehear its decision on the validity of US Patent No.

Valneva and IDT Biologika end COVID-19 manufacturing contract

BioPharma Reporter

Valneva and IDT Biologika have agreed to terminate their COVID-19 vaccine collaboration in light of reduced orders for the vaccine. Upstream Processing